Neuland Laboratories Limited
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
What Neuland files
- Others73
- Investor Meet46
- Important30
- Updates16
- Board Meeting8
- PPTs8
Neuland Labs kicked off FY27 with strong Q1 results! 1. **Business Performance:** Total Income soared 116.3% YoY to Rs. 650.1 Cr. PAT jumped an impressive 975.0% YoY to Rs. 147.4 Cr. EBITDA rose 448.2% YoY to Rs. 231.1 Cr, with margins expanding to 35.5%. Both CMS & GDS segments performed...
Neuland Labs delivered a strong show in FY26! Revenue jumped 37.1% YoY to Rs. 2053.1 Cr, with Profit After Tax (PAT) soaring 40% to Rs. 363.1 Cr. EBITDA margin expanded to a robust 29.4%. Growth was largely fueled by its Contract Manufacturing Solutions (CMS) business, driven by commercial molecules, and...
Neuland Laboratories reported Q3FY26 total income of Rs. 447.8 crore, up 11.4% YoY. However, EBITDA declined 6% YoY to Rs. 85 crore (19.0% margin) and PAT fell 60% YoY to Rs. 40.4 crore, attributed to product mix and higher operating expenses. For the nine months of FY26, total income grew...
**Business Performance:** Neuland Labs delivered a strong Q2FY26, with total income soaring 63.7% year-over-year to Rs 516.1 Cr and profit (PAT) jumping 201.6% to Rs 96.5 Cr. This stellar growth was primarily driven by commercial projects in its high-margin Custom Manufacturing Solutions (CMS) segment. In the Generic Drug Substance (GDS)...
**Financial Highlights:** Q1FY26 saw total income at Rs. 300.6 Cr (-32.4% YoY), EBITDA at Rs. 42.1 Cr (14% margin), and PAT at Rs. 13.7 Cr. Working capital days increased to 145 due to inventory. Management, while noting a "below par" Q1, anticipates healthy full-year growth, maintaining a net cash position....